Brief: Biocept Expands Commercial Offering Of Cnside™ Assay To Most Cancers That Metastasize To The Central Nervous System
17/10/2022 13:31
Biocept Inc BIOC.O :
* BIOCEPT EXPANDS COMMERCIAL OFFERING OF CNSIDE™ ASSAY TO
MOST
CANCERS THAT METASTASIZE TO THE CENTRAL NERVOUS SYSTEM
Source text for Eikon: ID:nBw7lG2jda
Further company coverage: BIOC.O
Recent news on Biocept
See all newsBrief: Biocept Says Trading Of Common Stock Will Be Suspended By Nasdaq At Opening Of Business On Oct 25
U.S. STOCKS ON THE MOVE-Overstock.com, Biocept, Birkenstock
Biocept slumps after filing for bankruptcy protection
Brief: Biocept CEO Antonino Morales Resigns
U.S. STOCKS ON THE MOVE-Albemarle, Novavax, WeWork